Successful Treatment of Chronic Eosinophilic Pneumonia with Anti-IgE Therapy.
10.3346/jkms.2012.27.10.1261
- Author:
Yoo Seob SHIN
1
;
Hyun Jung JIN
;
Hye Soo YOO
;
Eui Kyung HWANG
;
Young Hee NAM
;
Young Min YE
;
Hae Sim PARK
Author Information
1. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. hspark@ajou.ac.kr
- Publication Type:Case Reports ; Research Support, Non-U.S. Gov't
- Keywords:
Chronic Eosinophilic Pneumonia;
Anti-IgE Therapy
- MeSH:
Adolescent;
Adrenal Cortex Hormones/therapeutic use;
Antibodies, Anti-Idiotypic/*therapeutic use;
Cough/etiology;
Dyspnea/etiology;
Humans;
Male;
Pulmonary Eosinophilia/diagnosis/radiography/*therapy;
Tomography, X-Ray Computed;
Young Adult
- From:Journal of Korean Medical Science
2012;27(10):1261-1264
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anti-IgE therapy, using recombinant humanized anti-IgE antibodies, is clinically effective in patients with eosinophil-related disorders such as allergic asthma, allergic rhinitis, and chronic urticaria. Chronic eosinophilic pneumonia tends to respond promptly to systemic corticosteroid therapy, however; relapses are common following corticosteroid tapering. We treated two patients (17- and 19-yr-old males) of chronic eosinophilic pneumonia whose symptoms were cough and dyspnea on exertion. The symptoms were recurrent while tapering off corticosteroid. They were treated with anti-IgE antibody without recurrence for 2 yr and 15 months. Here, we first describe clinical experience of the 2 cases of chronic eosinophilic pneumonia.
